Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_4
2
67%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Withdrawn1
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 42 (66.7%)

Trials by Status

withdrawn133%
not_yet_recruiting133%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingphase_1

Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation

NCT07245381
recruitingphase_4

A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures

NCT06864130
withdrawnphase_4

The Effects of Alendronate After Cure of Primary Hyperparathyroidism

NCT00359385

Clinical Trials (3)

Showing 3 of 3 trials
NCT07245381Phase 1

Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation

Not Yet Recruiting
NCT06864130Phase 4

A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures

Recruiting
NCT00359385Phase 4

The Effects of Alendronate After Cure of Primary Hyperparathyroidism

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3